SecurityNVTR / Nuvectra Corporation (67075N108)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding14,260,449 shares (as of 2018-06-30)
Total Insiders15
Total Directors8
Total Officers7

Stock Insider Trading (from SEC Form 4)

Nuvectra Corporation insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

NVTR / Nuvectra Corporation insiders include MILLER JOSEPH A, BERGER WALTER Z, and PARKS FRED B, Hanchin Joseph Paul, Fahey Kathy Jo, Zelibor Thomas Edward, Bihl Anthony P III, Kosharek Jennifer Tremmel Jon T, GREATBATCH, INC., Kaula Norbert, DREES SCOTT F, JOHNSON DAVID D, Hickman Thomas Kelley, HAWARI KENNETH G, .

Insider Roster

Insider Dir Off 10% Shares Owned
Kosharek Jennifer Principal Accounting Officer
X 3,103
Kaula Norbert EVP, Research & Development
X 15,467
Hanchin Joseph Paul President
X 40,920
BERGER WALTER Z CFO
X 77,325
DREES SCOTT F CEO, Director
X X 189,296
Tremmel Jon T Director
X 7,538
PARKS FRED B Director
X 7,538
MILLER JOSEPH A Director
X 45,433
JOHNSON DAVID D Director
X 37,538
HAWARI KENNETH G Director
X 24,538
Bihl Anthony P III Director
X 10,977
Zelibor Thomas Edward Director
X 8,538
Hickman Thomas Kelley EVP, Sales & Marketing
X 3,442
Fahey Kathy Jo VP of Regulatory & Clinical
X 2,854
GREATBATCH, INC. 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-12 4 BERGER WALTER Z M D 18.14 1,036 77,325
2018-08-12 4 Hanchin Joseph Paul M D 18.14 797 40,920
2018-08-12 4 Kaula Norbert M D 18.14 2,141 15,467
2018-08-12 4 Kosharek Jennifer M D 18.14 442 3,103
2018-07-09 4 Zelibor Thomas Edward M D 17.36 838 8,538
2018-07-09 4 Bihl Anthony P III M D 17.36 838 10,977
2018-07-09 4 HAWARI KENNETH G M D 17.36 838 24,538
2018-07-09 4 JOHNSON DAVID D M D 17.36 838 37,538
2018-07-09 4 MILLER JOSEPH A M D 17.36 838 45,433
2018-07-09 4 PARKS FRED B M D 17.36 838 7,538
2018-07-09 4 Tremmel Jon T M D 17.36 838 7,538
2018-07-07 4 BERGER WALTER Z M D 18.09 8,012 76,289
2018-07-07 4 DREES SCOTT F M D 18.09 16,024 189,296
2018-07-07 4 Hanchin Joseph Paul M D 18.09 4,273 40,123
2018-05-17 4 Hanchin Joseph Paul S D 17.33 -1,541 35,850 621,280
2018-07-07 4 Kaula Norbert M D 18.09 499 13,326
2018-07-07 4 Kosharek Jennifer M D 18.09 175 2,661
2018-05-12 4 BERGER WALTER Z M D 16.73 4,141 68,277
2018-05-12 4 Hanchin Joseph Paul M D 16.73 3,185 37,391
2018-05-12 4 Kaula Norbert M D 16.73 8,559 12,827
2018-05-08 4 Zelibor Thomas Edward P D 16.50 1,000 7,700 127,050
2018-04-10 4 Bihl Anthony P III M D 13.53 837 10,139
2018-04-10 4 HAWARI KENNETH G M D 13.53 837 23,700
2018-04-10 4 JOHNSON DAVID D M D 13.53 837 36,700
2018-04-10 4 MILLER JOSEPH A M D 13.53 837 44,595
2018-04-10 4 PARKS FRED B M D 13.53 837 6,700
2018-04-10 4 Tremmel Jon T M D 13.53 837 6,700
2018-04-10 4 Zelibor Thomas Edward M D 13.53 837 6,700
2018-04-07 4 BERGER WALTER Z M D 13.05 8,012 64,136
2018-04-07 4 DREES SCOTT F M D 13.05 16,024 173,272
2018-04-07 4 Hanchin Joseph Paul M D 13.05 4,273 34,206
2018-04-07 4 Kaula Norbert M D 13.05 499 4,268
2018-01-10 4 Bihl Anthony P III M D 9.79 837 9,302
2018-01-10 4 HAWARI KENNETH G M D 9.79 837 22,863
2018-01-10 4 JOHNSON DAVID D M D 9.79 837 35,863
2018-01-10 4 MILLER JOSEPH A M D 9.79 837 43,758
2018-01-10 4 PARKS FRED B M D 9.79 837 5,863
2017-01-10 4 Tremmel Jon T M D 9.79 837 5,863
2018-01-10 4 Zelibor Thomas Edward M D 9.79 837 5,863
2018-01-07 4 BERGER WALTER Z M D 7.86 8,012 56,124
2018-01-07 4 DREES SCOTT F M D 7.86 16,024 157,248
2018-01-07 4 Hanchin Joseph Paul M D 7.86 4,273 29,933
2018-01-07 4 Kaula Norbert M D 7.86 499 3,769
2017-12-04 4 MILLER JOSEPH A M D 4.01 4,665 42,921
2017-10-10 4 Zelibor Thomas Edward M D 13.87 838 5,026
2017-10-10 4 Bihl Anthony P III M D 13.87 838 8,465
2017-10-10 4 HAWARI KENNETH G M D 13.87 838 22,026
2017-10-10 4 JOHNSON DAVID D M D 13.87 838 35,026
2017-10-10 4 MILLER JOSEPH A M D 13.87 838 38,256
2017-10-10 4 PARKS FRED B M D 13.87 838 5,026
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Nuvectra Corporation (NVTR) CEO Scott Drees on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2018 Nuvectra Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. (3-0)

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

2018-07-03 seekingalpha
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018. (27-2)

Why Nuvectra Is Monday’s Big Biotech Loser

2018-07-02 247wallst
Nuvectra Corp. (NASDAQ: NVTR) shares were crushed on Monday after the company announced an update on its U.S. Food and Drug Administration (FDA) premarket approval (PMA) application and its TÜV SÜD application for CE Mark in Europe for Virtis. (1-0)

Nuvectra Corporation's (NVTR) CEO Scott Drees on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good day, ladies and gentlemen and welcome to the Q1 2018 Nuvectra Earnings Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded. (1-0)